combination therapy

May 17, 2019

FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia ... Read more

September 19, 2018September 19, 2018

Rituxan-Revlimid Combo Effective in Treating Advanced Follicular Lymphoma, Study Shows

News

Patients with previously untreated follicular lymphoma may soon be able to replace a regimen of chemotherapy and Rituxan (rituximab) with Rituxan and Revlimid (lenalidomide) after a Phase 3 trial showed similar effectiveness for ... Read more

March 19, 2018March 19, 2018

MorphosSys Therapy and Revlimid Eliminate Cancer in a Third of DLBCL Patients, Phase 2 Trial Shows

News

A combination of MorphoSys‘ MOR208 and Revlimid (lenalidomide) eliminated cancer cells in almost a third of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a Phase 2 clinical trial shows. Tumor ... Read more

February 2, 2018February 2, 2018

Aggressive Treatment Seen to Help Advanced Follicular Lymphoma Patients in Phase 2 Trial

News

Sequential chemoimmunotherapy, radioimmunotherapy, and maintenance treatment with Rituxan (rituximab) improves progression-free survival and delays disease progression in patients with untreated advanced follicular lymphoma, Phase 2 clinical trial data shows. The study reporting ... Read more

September 18, 2017

Bayer Presents Copanlisib Combination Trials at Scientific Meeting

News

Two Phase 3 trials will assess the potential of Bayer’s copanlisib in combination with other treatment in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma, based on positive data from a ... Read more

December 10, 2015December 10, 2015

Treatment-Naive Follicular Lymphoma Patients Respond Well to Ibrutinib Combo Therapy

News

AbbVie has announced results from its Phase 2 clinical trial showing that the combination of ibrutinib (Imbruvica) and rituximab was well-tolerated and achieved an overall response rate of 82% in treatment-naïve patients with ... Read more

December 7, 2015

Last Week’s Top 3 Most Read Posts On Lymphoma

Read the Articles Here: Finding Out About Lymphoma Clinical Trials Mantle Cell Lymphoma Combination Therapy of Lenalidomide and Rituximab Shows Promise in New Study Lymphoma Study in Advanced Cancer Patients ... Read more